CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Lipid Sciences, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Lipid Sciences, Inc.
7068 Koll Center Parkway
Suite 401
Phone: (925) 249-4000p:925 249-4000 Plesanton, CA  94566  United States Fax: (302) 636-5454f:302 636-5454
This company's Plan of Liquidation went into effect on 1/17/2012
On 8/1/2013, the U.S. Securities and Exchange Commission revoked the registration of each class of registered securities of Lipid Sciences, Inc. for failure to make required periodic filings with the Commission.
This company is no longer actively traded on any major stock exchange.
Business Summary
Lipid Sciences, Inc. is a development-stage biotechnology company engaged in research and development of products and processes intended to treat major medical indications, such as cardiovascular disease and viral infections in which lipids, or fat components, play a key role. It focuses on applications of its technologies in two main areas: cardiovascular disease, using its HDL Therapy platform, and viral infections, using its Viral Immunotherapy platform. HDL Therapy focuses on developing treatments for the reversal of atherosclerosis, which is the cause of heart attacks, strokes and peripheral vascular disease. Lipid Sciences’ Viral Immunotherapy platform focuses on treatments for people suffering from conditions caused by lipid-enveloped viruses, such as Human Immunodeficiency Virus (HIV), Hepatitis B and Hepatitis C. It conducts investigational research into other applications of its technologies and continues to secure additional intellectual property rights in these areas.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/200812/31/2007YesYesYes--

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research
6531 Real estate agents and managers

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Vice President - Scientific Affairs Jo-AnnMaltais 59 8/1/2000 8/1/2000
Vice President - Business Development Dale L.Richardson 52 1/28/2003 7/1/2000
Chief Scientific Director H. BryanBrewer 69 10/2/2008 10/28/2002

Business Names
Business Name
Lipid Sciences, Inc.
NZ Corporation

General Information
Number of Employees: 17 (As of 12/31/2007)
Outstanding Shares: 37,125,348 (As of 7/31/2008)
Shareholders: 621
Stock Exchange: OTC
Federal Tax Id: 430433090
Fax Number: (302) 636-5454
Email Address: info@lipidsciences.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023